QLH12016, an investigational oral AR PROTAC, is being evaluated in combination with established hormonal agents (abiraterone acetate and enzalutamide) for advanced prostate cancer. The trial's focus on safety, tolerability, and preliminary antitumor activity positions it within a competitive landscape dominated by existing therapies. The prostate cancer market is substantial, with ongoing demand for novel treatments that can overcome resistance mechanisms associated with current therapies. Successful outcomes could enhance Qilu Pharmaceutical's portfolio and provide a strategic advantage in a market characterized by high unmet needs and significant competition from other emerging therapies.